Keeping up with the rules for peptides can feel like trying to read a map that's constantly being redrawn. As of late 2026, the FDA has been busy reviewing several popular compounds to decide where they fit in the world of compounding—which is just a fancy way of saying how pharmacies are allowed to custom-mix medications.
What is happening with BPC-157 and KPV?
If you have been following BPC-157, things have been moving quickly. As of September 2026, it is currently in a state of evolving review. In July 2026, the Pharmacy Compounding Advisory Committee (a group of experts that gives the FDA advice) reviewed it for the 503A Bulks List. This list basically determines what substances pharmacies can use to mix custom prescriptions for individual patients.
There are some specific safety hurdles the FDA is looking at for BPC-157:
- Immunogenicity concerns: This is when the body’s immune system has an unwanted reaction to a substance.
- Impurity issues: Worries about how pure the peptide actually is.
- Lack of human data: A general need for more safety information in people.
KPV is in a similar boat. After its initial nomination was withdrawn, it was also reviewed by the same committee in July 2026. The main concerns there involve limited information on how humans react to it and general safety uncertainties.
The latest on Semaglutide
While Semaglutide is FDA-approved (you might know it as Ozempic or Wegovy), the rules for custom-made versions have changed. The national shortage that allowed for more flexible compounding has ended.
FDA data shows some emerging safety signals being monitored for semaglutide, including:
- Nausea and Vomiting: These are strong, expected signals already on the label.
- Delayed Gastric Emptying: This means food stays in your stomach longer, which can affect how you absorb other pills.
- Pulmonary Aspiration: This is a risk during general anesthesia, which was added to the label in 2025.
- Eye Health: A signal for NAION (a condition affecting the optic nerve) is under review as of early 2025.
Other regulatory red flags
Several other compounds are currently in "Category 2," meaning the FDA has identified potential safety risks. For example, GHRP-2 and GHRP-6 are listed there due to immunogenicity concerns. Melanotan II is also in Category 2 following reports of multiple serious adverse events.
Many of these, including MK-677 and PEG-MGF, were also mentioned in 2020 warning letters sent to specific compounding pharmacies. This is a great one to bring up with your doctor. You can find peptide-experienced physicians in our Find a Doctor directory.
This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice. To find options in your area, you can search for a peptide doctor who understands these regulatory changes.
Referenced Peptides
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.